Immunotherapy: Constructive Approach for Breast Cancer Treatment

Area of Science:

• Immunology
• Oncology
• Biotechnology

Background:

• Immune checkpoint blockades (ICBs) have transformed breast cancer therapy, particularly for triple-negative breast cancer (TNBC).
• Tumor relapse and drug resistance remain significant challenges despite positive initial findings with PD-1/PD-L1 inhibitors.
• Cancer stem cells (CSCs) play a crucial role in tumor initiation and growth, presenting a target for overcoming resistance.

Purpose of the Study:

• To review current immunotherapeutic options for breast cancer.
• To explore molecular mechanisms of resistance to ICBs and advanced strategies to overcome them.
• To examine cancer stem cell antigens, markers, and the role of cancer vaccines in breast cancer treatment.

Main Methods:

• Literature review of existing immunotherapies, ICBs, and CSCs in breast cancer.
• Analysis of molecular mechanisms underlying resistance to ICBs.
• Synthesis of information on cancer stem cell antigens, markers, and vaccine development.

Main Results:

• ICBs show promise but limited efficacy in a subset of TNBC patients due to resistance.
• Understanding CSCs and their antigens offers potential strategies to enhance immunotherapy effectiveness.
• Various cancer vaccines are being developed targeting tumor antigens to induce active immunity.

Conclusions:

• Overcoming ICB resistance is critical for improving breast cancer treatment outcomes.
• Targeting CSCs and developing effective cancer vaccines are promising avenues for future breast cancer immunotherapies.
• Further research into resistance mechanisms and clinical trials are essential for advancing breast cancer immunotherapy.